NSE · INDOCO
Indoco Remedies Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹452 Cr with net profit ₹31 Cr — a 6.78% net margin, versus 20.13% the period before.
Shareholding
As of 2026-09-30
- Promoter58.92%
- Public22.8%
- FII1.64%
- DII16.64%
34,098 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.78× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #48 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Indoco Remedies Ltd.(this company) | ₹1,985 Cr | — | 1.95 | -7.71% | 1.71% |
AI analysis
AI-generated · google/gemini-2.5-flashIndoco Remedies Ltd., listed as INDOCO, has a market capitalization of Rs 2257 Cr. The company reported a revenue of Rs 1670.37 Cr with a profit margin of -5.31%. Its debt-to-equity ratio stands at 0.78.
Positives
- +No promoter shares are pledged, with promoter pledge at 0% as of June 30, 2026.
- +The dividend yield is 8%, indicating a return to shareholders.
Negatives
- −Revenue growth decreased by -8.4%.
- −The profit margin is negative at -5.31%.
- −The company reported a negative return on equity (ROE) of -10.13%.
- −Earnings per share (EPS) for March 2025 was negative at -8.45.
- −No quarterly results have been disclosed since March 2026.
Financial Performance
Indoco Remedies Ltd. reported an annual revenue of Rs 1670.37 Cr, marking a revenue growth decrease of -8.4%. The company experienced a net profit of -73.7369 Cr for the period ending March 2025. Quarterly, revenue was Rs 475.61 Cr in March 2026, with a net profit of -21.64 Cr. The EBITDA for the same quarter was 17.18.
Profitability & Returns
The company's profitability metrics show a negative profit margin of -5.31%. Return on equity (ROE) is -10.13%, and return on capital employed (ROCE) is 0.77%. The earnings per share (EPS) for the period ending March 2025 was -8.45.
Balance Sheet
The book value per share for Indoco Remedies Ltd. is Rs 101.76. The company has a debt-to-equity ratio of 0.78, indicating the proportion of debt used to finance its assets relative to shareholder equity.
Ownership & Pledges
Promoter holding in Indoco Remedies Ltd. stands at 58.8636% as of June 30, 2026. Public shareholding is 22.1824%. There are no reported promoter pledges.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.